{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:51:42Z","timestamp":1791157902676,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02822-1","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:02:32Z","timestamp":1791154952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics profiling reveals homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-0696","authenticated-orcid":false,"given":"Binhua","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunna","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saihua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1180-391X","authenticated-orcid":false,"given":"Juntao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2822_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ygyno.2016.12.003","volume":"144","author":"A Gadducci","year":"2017","unstructured":"Gadducci, A., Carinelli, S. & Aletti, G. Neuroendrocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists. Gynecol. Oncol. 144, 637\u2013646 (2017).","journal-title":"Gynecol. Oncol."},{"key":"2822_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.6004\/jnccn.2025.0057","volume":"23","author":"NR Abu-Rustum","year":"2025","unstructured":"Abu-Rustum, N. R. et al. Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 23, 549\u2013573 (2025).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"2822_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S1470-2045(23)00185-7","volume":"24","author":"T Chu","year":"2023","unstructured":"Chu, T. et al. The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry. Lancet Oncol. 24, 701\u2013708 (2023).","journal-title":"Lancet Oncol."},{"key":"2822_CR4","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ccell.2024.05.002","volume":"42","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Molecular subtypes of neuroendocrine carcinomas: a cross-tissue classification framework based on five transcriptional regulators. Cancer Cell 42, 1106\u20131125.e8 (2024).","journal-title":"Cancer Cell"},{"key":"2822_CR5","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.bj.2023.100633","volume":"46","author":"A Chao","year":"2023","unstructured":"Chao, A., Wu, R.-C., Lin, C.-Y., Chang, T.-C. & Lai, C.-H. Small cell neuroendocrine carcinoma of the cervix: from molecular basis to therapeutic advances. Biomed. J. 46, 100633 (2023).","journal-title":"Biomed. J."},{"key":"2822_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102011","volume":"35","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi, M. et al. Clinical and pathological characteristics and outcomes of small cell neuroendocrine carcinoma of the uterine cervix. Int. J. Gynecol. Cancer 35, 102011 (2025).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2822_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02471-y","volume":"24","author":"F Chen","year":"2025","unstructured":"Chen, F. et al. Integrated multi-omics identifies a CD54+ iCAF-ITGAL+ macrophage niche driving immunosuppression via CXCL8-PDL1 axis in cervical cancer. Mol. Cancer 24, 262 (2025).","journal-title":"Mol. Cancer"},{"key":"2822_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2321898121","volume":"121","author":"S Bellone","year":"2024","unstructured":"Bellone, S. et al. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. USA 121, e2321898121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2822_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/1878-0261.12962","volume":"16","author":"AM Schultheis","year":"2022","unstructured":"Schultheis, A. M. et al. Genomic characterization of small cell carcinomas of the uterine cervix. Mol. Oncol. 16, 833\u2013845 (2022).","journal-title":"Mol. Oncol."},{"key":"2822_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33359-w","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Human papillomavirus integration perspective in small cell cervical carcinoma. Nat. Commun. 13, 5968 (2022).","journal-title":"Nat. Commun."},{"key":"2822_CR11","doi-asserted-by":"publisher","first-page":"e0234505","DOI":"10.1371\/journal.pone.0234505","volume":"15","author":"RT Hillman","year":"2020","unstructured":"Hillman, R. T. et al. Comparative genomics of high grade neuroendocrine carcinoma of the cervix. PLoS ONE 15, e0234505 (2020).","journal-title":"PLoS ONE"},{"key":"2822_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ygyno.2021.04.019","volume":"161","author":"X Pei","year":"2021","unstructured":"Pei, X. et al. The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix. Gynecol. Oncol. 161, 779\u2013786 (2021).","journal-title":"Gynecol. Oncol."},{"key":"2822_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/path.6290","volume":"263","author":"B Pan","year":"2024","unstructured":"Pan, B. et al. Multiomics sequencing and immune microenvironment characteristics define three subtypes of small cell neuroendocrine carcinoma of the cervix. J. Pathol. 263, 372\u2013385 (2024).","journal-title":"J. Pathol."},{"key":"2822_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell 187, 184\u2013203.e28 (2024).","journal-title":"Cell"},{"key":"2822_CR15","first-page":"23","volume":"7","author":"BA Martinez-Cannon","year":"2024","unstructured":"Martinez-Cannon, B. A. & Colombo, I. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer. Cancer Drug Resist. 7, 23 (2024).","journal-title":"Cancer Drug Resist."},{"key":"2822_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/ijgc-2020-001649","volume":"30","author":"MR Carroll","year":"2020","unstructured":"Carroll, M. R. et al. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. Int. J. Gynecol. Cancer 30, 1303\u20131307 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2822_CR17","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","volume":"31","author":"G Attard","year":"2025","unstructured":"Attard, G. et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat. Med. 31, 4109\u20134118 (2025).","journal-title":"Nat. Med."},{"key":"2822_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62295-8","volume":"16","author":"P Li","year":"2025","unstructured":"Li, P. et al. OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer. Nat. Commun. 16, 7209 (2025).","journal-title":"Nat. Commun."},{"key":"2822_CR19","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk, B. J. et al. A randomized, Phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J. Clin. Oncol. 40, 3952\u20133964 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2822_CR20","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41588-023-01460-5","volume":"55","author":"P Bland","year":"2023","unstructured":"Bland, P. et al. SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response. Nat. Genet. 55, 1311\u20131323 (2023).","journal-title":"Nat. Genet."},{"key":"2822_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","volume":"559","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann, M. et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 559, 285\u2013289 (2018).","journal-title":"Nature"},{"key":"2822_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk8908","volume":"10","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity. Sci. Adv. 10, eadk8908 (2024).","journal-title":"Sci. Adv."},{"key":"2822_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29629-2","volume":"13","author":"S Cohen","year":"2022","unstructured":"Cohen, S. et al. A POLD3\/BLM dependent pathway handles DSBs in transcribed chromatin upon excessive RNA:DNA hybrid accumulation. Nat. Commun. 13, 2012 (2022).","journal-title":"Nat. Commun."},{"key":"2822_CR24","doi-asserted-by":"publisher","first-page":"9695","DOI":"10.1093\/nar\/gkae642","volume":"52","author":"F Liang","year":"2024","unstructured":"Liang, F., Rai, R., Sodeinde, T. & Chang, S. TRF2-RAP1 represses RAD51-dependent homology-directed telomere repair by promoting BLM-mediated D-loop unwinding and inhibiting BLM-DNA2-dependent 5\u2019-end resection. Nucleic Acids Res. 52, 9695\u20139709 (2024).","journal-title":"Nucleic Acids Res."},{"key":"2822_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add7872","volume":"15","author":"N Gupta","year":"2023","unstructured":"Gupta, N. et al. BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer. Sci. Transl. Med. 15, eadd7872 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2822_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-024-07802-5","volume":"635","author":"J Tang","year":"2024","unstructured":"Tang, J. et al. Enhancing transcription-replication conflict targets ecDNA-positive cancers. Nature 635, 210\u2013218 (2024).","journal-title":"Nature"},{"key":"2822_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","volume":"628","author":"M Petropoulos","year":"2024","unstructured":"Petropoulos, M. et al. Transcription-replication conflicts underlie sensitivity to PARP inhibitors. Nature 628, 433\u2013441 (2024).","journal-title":"Nature"},{"key":"2822_CR28","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.molcel.2023.05.026","volume":"83","author":"JM Schvartzman","year":"2023","unstructured":"Schvartzman, J. M. et al. Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination. Mol. Cell 83, 2347\u20132356.e8 (2023).","journal-title":"Mol. Cell"},{"key":"2822_CR29","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.stem.2021.03.012","volume":"28","author":"K L\u00f5hmussaar","year":"2021","unstructured":"L\u00f5hmussaar, K. et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell Stem Cell 28, 1380\u20131396.e6 (2021).","journal-title":"Cell Stem Cell"},{"key":"2822_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.05.004","volume":"11","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. Gp130-dependent STAT3 activation in M-CSF-derived macrophages exaggerates tumor progression. Genes Dis. 11, 100985 (2023).","journal-title":"Genes Dis."},{"key":"2822_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ygyno.2011.04.011","volume":"122","author":"GJ Gardner","year":"2011","unstructured":"Gardner, G. J., Reidy-Lagunes, D. & Gehrig, P. A. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol. Oncol. 122, 190\u2013198 (2011).","journal-title":"Gynecol. Oncol."},{"key":"2822_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4447-x","volume":"18","author":"CB Tempfer","year":"2018","unstructured":"Tempfer, C. B. et al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature. BMC Cancer 18, 530 (2018).","journal-title":"BMC Cancer"},{"key":"2822_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5147-2","volume":"19","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Lv, Z. & Lou, H. The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population. BMC Cancer 19, 22 (2019).","journal-title":"BMC Cancer"},{"key":"2822_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkag272","volume":"54","author":"F Liang","year":"2026","unstructured":"Liang, F. & Chang, S. TRF2-RAP1 inhibits homology-directed repair of telomeres by promoting BLM-mediated removal of telomere R-loops. Nucleic Acids Res. 54, gkag272 (2026).","journal-title":"Nucleic Acids Res."},{"key":"2822_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","volume":"25","author":"F Klemm","year":"2015","unstructured":"Klemm, F. & Joyce, J. A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 25, 198\u2013213 (2015).","journal-title":"Trends Cell Biol."},{"key":"2822_CR36","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s10753-024-02192-2","volume":"48","author":"H Long","year":"2025","unstructured":"Long, H. et al. IL-6 exacerbates oxidative damage of RPE cells by indirectly destabilizing the mRNA of DNA repair genes. Inflammation 48, 2323\u20132340 (2025).","journal-title":"Inflammation"},{"key":"2822_CR37","doi-asserted-by":"publisher","first-page":"100499","DOI":"10.1016\/j.gore.2019.100499","volume":"30","author":"PG Rose","year":"2019","unstructured":"Rose, P. G. & Sierk, A. Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing. Gynecol. Oncol. Rep. 30, 100499 (2019).","journal-title":"Gynecol. Oncol. Rep."},{"key":"2822_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/ijgc-2022-004050","volume":"33","author":"O Touhami","year":"2023","unstructured":"Touhami, O., Plante, M., St-Gelais, J. & Frumovitz, M. Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix. Int. J. Gynecol. Cancer 33, 623\u2013627 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2822_CR39","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1002\/cam4.4034","volume":"10","author":"X Ji","year":"2021","unstructured":"Ji, X. et al. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer. Cancer Med. 10, 4743\u20134751 (2021).","journal-title":"Cancer Med."},{"key":"2822_CR40","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/ijgc-2020-001649","volume":"30","author":"MR Carroll","year":"2020","unstructured":"Carroll, M. R. et al. PARP and PD-L1 as potential therapeutic targets for women with neuroendocrine cervical cancer. Int. J. Gynecol. Cancer 30, 1303\u20131307 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2822_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","volume":"20","author":"NA Karim","year":"2025","unstructured":"Karim, N. A. et al. Phase II randomized study of maintenance atezolizumab versus atezolizumab plus talazoparib in patients with SLFN11 positive extensive-stage SCLC: S1929. J. Thorac. Oncol. 20, 383\u2013394 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"2822_CR42","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1007\/s00259-024-06844-1","volume":"51","author":"H Rauch","year":"2024","unstructured":"Rauch, H. et al. Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 51, 4099\u20134110 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2822_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13046-020-01728-2","volume":"39","author":"L Ma","year":"2020","unstructured":"Ma, L., Bian, X. & Lin, W. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. J. Exp. Clin. Cancer Res. 39, 219 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2822_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-022-01291-7","volume":"15","author":"N Xu","year":"2022","unstructured":"Xu, N. et al. Integrated proteogenomic characterization of urothelial carcinoma of the bladder. J. Hematol. Oncol. 15, 76 (2022).","journal-title":"J. Hematol. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02822-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02822-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02822-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:02:33Z","timestamp":1791154953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02822-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2822"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02822-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"424"}}